Refer patients

UK_Therapy Areas_Think FA_Refer patients_PAGE

This site is intended for Healthcare Professionals in the UK and Ireland. If you are a member of the public, please [click here](https://biogenlinc.co.uk/public).
Details of how to report adverse events are available at the bottom of the page.

UK disclaimer text

UK audience disclaimer Think FA

UK audience disclaimer Think FA with PI button UK_EXTERNAL LINK

UK audience disclaimer Think FA with PI button ROI_EXTERNAL LINK

Master Metadata [AUDIENCE - External Vendor, General Practitioners, Neurologist, Nurses, Paediatric Neurologist, Paediatrician, Pharmacists, Physicians, Physiotherapist] RESOURCE SET

Master Metadata [CONTENT TYPE - MEDICAL EDUCATION] RESOURCE SET

Tysabri Patient hubs [FORMAT - Text, Interactive] RESOURCE SET

Master Metadata [FORMAT - Text, Interactive] RESOURCE SET

UK_Therapy Areas_Think FA_Refer patients_PAGE_2025_EN

Master Metadata [MARKET - UK + IRELAND] RESOURCE SET

Master Metadata [PRODUCT - Skyclarys] RESOURCE SET

Master Metadata [PROMO - PROMO] RESOURCE SET

Master Metadata [REGION - EU+REGION] RESOURCE SET

Master Metadata [SCIENTIFIC CONTENT - YES] RESOURCE SET

Master Metadata [TA - Friedreich-Ataxie] RESOURCE SET

Friedreich-Ataxie

Therapy Areas

Think FA Home

UK_Therapy Areas_Think FA_Refer Patients_SEO DATA

Think Friedreich's ataxia (FA) | Why Refer Patients

UK_Therapy Areas_Think FA_Refer Patients_LANDING PAGE

DotGrid Think FA Desktop

DotGrid Think FA Mobile

UK_Therapy Areas_Think FA_Refer Patients_BUBBLE INTRO

UK_Therapy Areas_Think FA_NAVIGATION_TAGS ITEM

Help your patients receive the care they need

UK_Therapy Areas_Think FA_Refer Patients_Elizabeth Banner_GRID SECTION

UK_Therapy Areas_Think FA_Refer Patients_Earlier referral_LAYOUT SECTION

Earlier referral to a specialist ataxia centre can have a significant impact on your FA patients by facilitating:1,2

### A large natural history study of FA showed a measurable timeline for loss of function9

- The Friedreich’s Ataxia Clinical Outcome Measures Study (FA-COMS) followed FA patients annually for 5 years.9
- Progression was evaluated using mFARS, a scale developed to measure progression of FA in clinical trials, which provides a detailed evaluation of a patient’s overall disease status.9,10
- Each point change in the mFARS translates to impact on patient function and daily activities.10
- All patients experienced FA progression, regardless of age9

<style>
.jTbcwc {
 mask-image: none !important;
 background-color: transparent !important;
 width: 0 !important;
 height: 0 !important;
 flex-shrink: 1 !important;
}
 </style>

UK_Therapy Areas_Think FA_Refer Patients_Large natural history_LAYOUT SECTION

UK_Therapy Areas_Think FA_Refer Patients_Footnote & References_GRID SECTION